Abstract
Amyloidosis is defined as the cascade of structural changes of proteins leading to the formation of insoluble fibril aggregates that accumulate in tissue as amyloid plaques. All types of amyloidosis are structurally characterized by the cross β-pleated sheet conformation of the fibrils irrespective of their biochemical composition (reviewed by Glenner, 1980). This common structural feature of fibril aggregates is the basis of their insolubility and relative resistance to proteolytic digestion (Jarrett and Lansbury, 1993; Nordstedt et al., 1994). Amyloid plaque formation and deposition is believed to be the key event in nerve cell death in chronic and incurable neurodegenerative diseases such as Alzheimer’s Disease (AD) (reviewed by Scikoe, 1996) and Creutzfeldt-Jakob Disease (CJD) (reviewed by Prusiner, 1996). One of the major therapeutic approaches to arrest, or at least slow down the progression of these devastating diseases, is to stop proteins from aggregating into amyloid fibrils.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Chartier-Harlin, M.C., Crawford, F., Houlden, H., Warren, A., Hughes, D., Fidani, L., Goate, A., Rossor, M., Roques, P., Hardy, J., and Mullan, M., 1991, Early-onset Alzheimer’s Disease caused by mutations at codon 717 of the β-Amyloid Precursor Protein gene. Nature 353:844–846.
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A.Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., and Scikoe D.J., 1992, Mutation of the β-Amyloid Precursor Protein in familial Alzheimer’s Disease increases β-protein production. Nature 360:672–674.
Cummings, B.J., Pike, C.J., Shankle, R., and Cotman, C.W., 1996, β-Amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer’s Disease. Neurobiol. Aging 17(6), 921–933.
Forloni, G., Angeretti, N., Chiesa, R., Monzani, E., Salmona, M, Bugiani, O., and Tagliavini, F., 1993, Neuro-toxicity of a prion protein fragment. Nature 362:543–546.
Forloni, G., Del Bo, R., Angeretti, N., Chiesa, R., Smiroldo, S., Doni, R., Ghibaudi, A., Salmona, M., Porro, M., Verga, L., Giaccone, G., Bugiani, O., and Tagliavini, F., 1994, A neurotoxic prion protein fragment induces rat astroglial proliferation and hypertrophy. EurJ.Neurosci. 6:1415–1422.
Games, D., Adams, D., Alessandrini, R., Barbour, R., Berthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., Guido, T., Hagoplan, S., Johnson-Wood, K., Khan, K., Lee, M, Leibowitz, P., Lieder-burg, I., Little, S., Masliah, E., McConlogue, L., Montoya-Zavala, M., Mucke, L., Paganini, L., Penniman, E., Power, M., Schenk, D., Seubert, P., Snyder, B., Soriano, F., Tan, H., Vitale, J., Wadsworth, S., Wolozin, B., and Zhao, J., 1995, Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-Amyloid Precursor Protein. Nature 373:523–527.
Ghetti, B., Piccardo, P., Frangione, B., Bugiani, O., Giaccone, G., Young, K., Prelli, F., Farlow, M.R., Dlouhy, R., and Tagliavini, F., 1996, Prion protein amyloidosis. Brain Pathol. 6:127–145.
Giaccone, G., Tagliavini, F., Lindoli, G., Bouras, C., Frigerio, L., Frangione, B., and Bugiani, O., 1989, Down Patients: extracellular preamyloid deposits precede neuritic degeneration and senile plaques. Neurosci.Lett. 97:232–238.
Gianni, L., Bellotti, V., Gianni, A.M., and Merlini, G.P., 1995, New drug therapy of amyloidosis: Resorption of AL-type deposits with 4′-iodo-4′-deoxydoxorubicin. Blood 3:855–861.
Glenner, G.G., 1980, Amyloid deposits and amyloidosis (First part). NewEngl. J. Med. 302(23): 1283–1292.
Glenner, G.G., 1980, Amyloid deposits and amyloidosis (Second part). NewEngl. J. Med. 302(24): 1333–1343.
Glenner, G.G., and Wong, C.W., 1984, Alzheimer’s Disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem.Biophys. Res.Comm. 120(3):885–890.
Goate, A., Chartier-Harlin, M.C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., Mant, R., Newton, P., Rooke, K., Roques, P., Talbot, C., Pericak-Vance, M., Roses, A., Williamson, R., Rossor, M., Owen, M., and Hardy, J., 1991, Segregation of a missence mutation in the Amyloid Precursor Protein gene with Familial Alzheimer’s Disease. Nature 349:704–707.
Haass, C., Hung, A.Y., Scikoe, D.J., and Teplow D.B., 1994, Mutations associated with a locus for Familial Alzheimer’s Disease result in alternative processing of Amyloid-β Protein Precursor. J.Biol.Chem. 269: 17741–17748.
Jarrett, J.L., and Lansbury, P.T. Jr., 1993, Seeding “one-dimensional crystallization” of amyloid: a pathogenic mechanism in Alzheimer’s Disease and scrapie? Cell 73:1055–1058.
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., and Cole, G., 1996, Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274:99–102.
Masters, C.L., Simms, G., Weinman, N.A., Multhaup, G., McDonald, B.L., and Beyreuther, K., 1985, Amyloid plaque core protein in Alzheimer Disease and Down Syndrome. Proc. Natl. Acad. Sci. USA, 82:4245–4249.
Merlini, G.P., Ascari, E., Amboldi, N., Bellotti, V., Arbastini, E., Perfetti, V., Ferrari, M., Zorzoli, I., Marinone, M.G., Garini, P., Diegoli, M., Trizio D., and Ballinari, D., 1995, Interaction of the anthracycline 4′-Iodo-4′-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc. Natl Acad. Sci. USA, 92:2959–2963.
Mullan, M., Crawford, F., Axelman, K., Houlden, H., Lillius, L., Winblad, B., and Lannfelt, L., 1992, A pathogenic mutation for probable Alzheimer’s Disease in the APP gene at the N-terminus of β-amyloid. Nat. Genet 1:345–347.
Nordstedt, C., Näslund, J., Tjernberg, L.O., Karlström, A.R., Thyberg, J., and Terenius, L., 1994, The Alzheimer Aβ peptide develops protease resistance in association with its polymerization into fibrils, J. Biol Chem. 269(49), 30773–30776.
Pike, C.J., Burdick, D., Walencewicz, A.J., Glabe, C.G., and Cotman, C.W., 1993, Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13:1676–1687.
Price, D.L., Sisodia, S.S., and Gandy, S.E., 1995, Amyloid beta amyloidosis in Alzheimer’s Disease. Curr. Opin. Neurol 8:268–274.
Prusiner, S.B., McKinley, M.P., Bowman, K.A., Bolton, D.C., Bendeheim, B.E., Groth, D.F., and Glenner G.G., 1983, Scrapie prion aggregate to form amyloid-like birefringent rods. Cell 35:349–358.
Prusiner, S.B., 1991, Molecular biology of prion diseases. Science 251:1515–1522.
Prusiner, S.B., 1996, Prion biology and Diseases’Laughing cannibals, mad cows, and scientific heresy. Med. Res. Rev. 16(5):487–505.
Rumble, B., Retallack, R., Hilbich, C., Simms, G., Multhaup, G., Martins, R., Hockey, A., Montgomery, P., Beyreuther, K., and Masters, C.L., 1989, Amyloid A4 protein and its precursor in Down’s Syndrome and Alzheimer’s Disease. N Engl. J. Med. 320:1446–1452.
Scheuner, D., Eckman, C, Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T.D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, E., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Scikoe, D., and Younkin, S., 1996, Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer’s Disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to Familial Alzheimer’s Disease. Nat. Med. 2(8):864–869.
Scikoe, D.J., 1991, The molecular pathology of Alzheimer’s Disease. Neuron 6:487–488.
Scikoe, D.J., 1996, Amyloid β-protein and the genetics of Alzheimer’s Disease. J. Biol. Chem. 271(31), 18295–18298.
Suzuki, N., Cheung, T.T., Cai, X.D., Odaka, A., Otvos, L. Jr., Eckman C., Golde, T.E., and Younkin, S.G., 1994, An increased percentage of long amyloid-β protein secreted by Familial Amyloid-β Precursor Protein (βAPP717) mutants. Science 264:1336–1340.
Tagliavini, F., McArthur, R.A., Canciani, B., Giaccone, G., Porro, M., Bugiani, M., Lievens, P.M., Bugiani, O., Peri, E., Dall’Ara, P., Rocchi, M., Poli, G., Forloni, G., Bandiera, T., Varasi, M., Suarato, A., Cassutti, P., Cervini, M.A., Lansen, J., Salmona, M., and Post, C., 1997, Effectiveness of anthracycline against experimental Prion Disease in Syrian Hamsters. Science 276:1119–1122.
Tanzi, R.E., Kovacs, D.M., Kim, T.W., Moir, R.D., Guenette, S.Y., and Wasco, W., 1996, The Presenelin Genes and their Roler in Early-Onset Familial Alzheimer’s Disease. Alz. Dis. Rev. 1:91–98.
Wisniesky, H.M., and Terry, R.D., 1973, Reexamination of the pathogenesis of the senile plaques. Prog. Neuropathol. 11:1–26.
Wisniesky, H.M., Morets, R.C., Lossinsky, A.S., 1981, Evidence for induction of localized amyloid deposits and neuritic plaques by an infectious agent. Ann. Neurol. 10:517–522.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Post, C. et al. (1998). Anthracyclines and Amyloidosis. In: Fisher, A., Hanin, I., Yoshida, M. (eds) Progress in Alzheimer’s and Parkinson’s Diseases. Advances in Behavioral Biology, vol 49. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5337-3_29
Download citation
DOI: https://doi.org/10.1007/978-1-4615-5337-3_29
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7435-0
Online ISBN: 978-1-4615-5337-3
eBook Packages: Springer Book Archive